Guide — Labs & Diagnostics
Coagulation Studies Before Respiratory Procedures
Arterial puncture, bronchoscopy, thoracentesis, and chest-tube insertion all carry bleeding risk. This guide walks the coagulation screen — PT/INR, aPTT, and the platelet count — what each test measures, the anticoagulants that change them, and the bedside thresholds that flag the patient who needs correction first.
8 min read · Labs & Diagnostics
Written by Apex Respiratory Editorial Team
Educational use only. This material supports respiratory therapy education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional protocols, or physician orders. Always follow facility policies and current provider orders, and verify calculations independently before clinical use.
Overview
Several procedures that respiratory therapists either perform or assist with carry a real risk of bleeding: arterial puncture for an arterial blood gas, arterial-line placement, bronchoscopy — especially with biopsy — thoracentesis, and chest-tube insertion. A quick coagulation screen run before any of these procedures identifies the patient who needs correction or extra caution before a needle goes in, rather than after bleeding has already started.
Three labs do most of the work at the bedside: the PT with its standardized INR, the aPTT, and the platelet count. Read alongside the patient’s anticoagulant list, they tell you whether the planned procedure can proceed, whether it should be held for correction, or whether you simply need to hold pressure longer afterward.
The coagulation tests
Each test reflects a different part of the clotting cascade, and each is prolonged by a different set of problems. Knowing which is which lets you match an abnormal value to the most likely cause without guessing.
| Test | What it measures | Normal range | Prolonged by |
|---|---|---|---|
| PT / INR | Extrinsic and common pathway; INR is the standardized PT | PT ~11-13.5 s; INR ~0.8-1.1 | Warfarin, liver disease, vitamin K deficiency |
| aPTT | Intrinsic and common pathway | ~25-35 s | Unfractionated heparin |
| Platelet count | Number of platelets (not platelet function) | 150,000-400,000/microL | Thrombocytopenia from many causes |
A few points are worth keeping straight. The PT and INR assess the extrinsic and common pathway and are prolonged by warfarin, liver disease, and vitamin K deficiency; the warfarin therapeutic range is typically an INR of 2–3. The aPTT assesses the intrinsic and common pathway and is prolonged by unfractionated heparin. The platelet count reflects how many platelets are present, not how well they work. Where more detail is needed, fibrinogen and — where available — viscoelastic testing such as TEG or ROTEM round out the picture.
Anticoagulants and what they do to the labs
The biggest source of bedside error is assuming the coagulation screen captures every anticoagulant. It does not. Match the drug to the test it actually moves — and recognize the agents that hide from routine labs entirely.
- Warfarin. Prolongs the INR. Reverse with vitamin K, and urgently with prothrombin complex concentrate when rapid correction is needed before a procedure.
- Unfractionated heparin. Prolongs the aPTT. Reverse with protamine, and hold the infusion before a procedure.
- Low-molecular-weight heparin (enoxaparin). Not reliably reflected by routine labs. Hold it by time relative to the last dose, and use an anti-Xa level if confirmation is needed.
- Direct oral anticoagulants (apixaban, rivaroxaban, dabigatran).Not reliably reflected by routine PT/INR or aPTT, so a normal screen does not exclude an active effect — dabigatran (a direct thrombin inhibitor) often prolongs the aPTT and thrombin time, and the factor Xa inhibitors variably prolong the PT, but no routine test reliably quantifies the drug level. Manage them by the specific drug, the dose timing, and the patient’s renal function, with targeted reversal agents — idarucizumab for dabigatran and andexanet for the factor Xa inhibitors. Use a calibrated anti-Xa level (for the Xa inhibitors) or a dilute thrombin or ecarin clotting time (for dabigatran) when a drug level is genuinely needed.
Practical thresholds at the bedside
The numbers below are common reference points, but they are institution-specific. Always verify your local policy before acting on any single threshold.
- Higher-risk procedures. Bronchoscopy with transbronchial biopsy and chest-tube placement commonly use a platelet count above roughly 50,000/microL and an INR below about 1.5 as minimum thresholds.
- Lower-risk procedures. Arterial puncture and arterial-line placement are usually acceptable even with anticoagulation, provided firm, prolonged pressure is held afterward. Caution rises with a markedly elevated INR or a very low platelet count.
- Biopsy versus no biopsy. Bronchoscopy without biopsy carries a lower bleeding risk than bronchoscopy with biopsy, so the threshold you apply depends on what the procedure actually involves.
What the RT does with it
Before an arterial puncture — the procedure RTs own most directly — the coagulation picture should drive a few concrete actions:
- Review the labs and the medication list together. Check the platelet count, the INR and aPTT, and the patient’s anticoagulant list before you puncture, so an out-of-range value is caught before the needle.
- Choose a compressible site.Use a site you can compress — the radial artery after a modified Allen test — rather than a non-compressible one, and hold firm pressure afterward, longer when the patient is anticoagulated.
- Escalate when labs are out of range. For an elective procedure, bring out-of-range coagulation values to the team before proceeding rather than working around them.
- Remember the DOACs. Recognize that the direct oral anticoagulants hide from the standard coagulation screen, so a normal PT/INR and aPTT do not clear a patient who is on one of them.
Common Pitfalls
- Assuming a normal screen excludes a DOAC effect. A normal PT and aPTT do not rule out apixaban, rivaroxaban, or dabigatran. The drug can be fully active with completely unremarkable routine coagulation labs.
- Forgetting that LMWH is invisible on routine coags. Enoxaparin is not reflected by the PT/INR or aPTT. Manage it by time since the last dose and, if needed, an anti-Xa level.
- Skimping on post-puncture pressure. The anticoagulated patient needs firm pressure held longer, not the same brief hold used for everyone else.
- Treating institutional thresholds as universal. The ~50,000 platelet and INR <1.5 numbers are common starting points, not fixed rules. Verify the policy at your own facility.
Board Exam Pearls
- PT/INR tracks warfarin. An elevated INR points to warfarin, liver disease, or vitamin K deficiency.
- aPTT tracks heparin. A prolonged aPTT points to unfractionated heparin.
- DOACs are not reliably reflected by PT/INR or aPTT. A normal screen does not exclude an effect (though dabigatran often prolongs the aPTT). Manage them by drug, dose timing, and renal function.
- ~50,000 platelets and INR <1.5 are typical minimums for higher-risk procedures.
- Hold pressure longer when anticoagulated. The simplest protection against a bleed after a compressible-site puncture.
FAQ
Which coagulation test tracks heparin versus warfarin?
The aPTT tracks unfractionated heparin, while the PT and its standardized INR track warfarin. A patient on a heparin drip should show a prolonged aPTT, and a patient on warfarin should show an elevated INR. Knowing which test reflects which drug lets you read the labs against the medication list at a glance.
Do the direct oral anticoagulants show up on a PT or aPTT?
No. Apixaban, rivaroxaban, and dabigatran are not reliably captured by routine PT/INR or aPTT, so a normal coagulation screen does not rule out an active DOAC effect. These drugs are managed by knowing the agent, the dose timing, and the patient's renal function, with specific reversal agents available — idarucizumab for dabigatran and andexanet for the factor Xa inhibitors.
What platelet count is needed before a bronchoscopy with biopsy?
Higher-risk procedures such as bronchoscopy with transbronchial biopsy and chest-tube placement commonly use a platelet count above roughly 50,000/microL and an INR below about 1.5 as minimum thresholds. These numbers are institution-specific, so always verify your local policy — bronchoscopy without biopsy carries a lower bleeding risk than biopsy.
Is an arterial blood gas safe in an anticoagulated patient?
Arterial puncture and arterial-line placement are lower-risk procedures and are usually acceptable even with anticoagulation, provided firm, prolonged pressure is held afterward at a compressible site such as the radial artery. Caution rises with a markedly elevated INR or a very low platelet count, and you should hold pressure longer when the patient is anticoagulated.
Related Resources
Sources
- Kacmarek RM, Stoller JK, Heuer AJ. Egan's Fundamentals of Respiratory Care. 12th ed. Elsevier; 2021. Hemodynamic monitoring and invasive procedures; arterial puncture.
- Patel IJ, Rahim S, Davidson JC, et al. Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions. J Vasc Interv Radiol. 2019;30(8):1168-1184.